Trial Profile
Phase II clinical study of RG3502 in HER2 positive patients with locally advanced/recurrent or metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2017
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 21 May 2016 New trial record